Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Abstract

TO THE EDITOR: Systemic amyloid light-chain amyloidosis (AL) is characterized by deposition of misfolded immunoglobulin light chains within organs. AL with an immunoglobulin M (IgM) monoclonal protein (IgM-AL) accounts for 5% to 7% of AL and exhibits more prevalent lymph node, neuropathic, and lung